Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer

Item
http://www.wikidata.org/entity/Q34608976
A Perspective of Immunotherapy for Prostate CancerTasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospectsSystemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine modelsThe anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growthIdentification of small molecule inhibitors for influenza a virus using in silico and in vitro approaches.The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer.Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies.Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients.Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer.Applying dried blood spot sampling with LCMS quantification in the clinical development phase of tasquinimod.A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.Neutrophils and the S100A9 protein critically regulate granuloma formation
P2860

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer

Item
http://www.wikidata.org/entity/Q34608976
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Long-term survival and biomark ...... tion-resistant prostate cancer
@ast
Long-term survival and biomark ...... tion-resistant prostate cancer
@en
Long-term survival and biomark ...... tion-resistant prostate cancer
@nl
type
label
Long-term survival and biomark ...... tion-resistant prostate cancer
@ast
Long-term survival and biomark ...... tion-resistant prostate cancer
@en
Long-term survival and biomark ...... tion-resistant prostate cancer
@nl
prefLabel
Long-term survival and biomark ...... tion-resistant prostate cancer
@ast
Long-term survival and biomark ...... tion-resistant prostate cancer
@en
Long-term survival and biomark ...... tion-resistant prostate cancer
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P932
P356
P1433
P1476
Long-term survival and biomark ...... tion-resistant prostate cancer
@en
P2093
P2860
P304
P31
P356
10.1158/1078-0432.CCR-13-1581
P407
P433
P478
P577
P698
P921
P932